Structure Therapeutics Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)




· · YEAR ENDED DECEMBER 31,
· · 2025 · · 2024 · · 2023
Cash flows from operating activities
Net loss	$(141,202)	$(122,526)	$(89,620)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	28,991	18,794	8,191
Depreciation expense	1,333	992	295
Accretion of asset retirement obligation	345	4	21
Non-cash lease expense	2,211	1,601	634
Accretion of net investment discounts	(15,587)	(18,465)	(5,975)
Gains on sale of non-financial assets	(10,249)	—	—
Changes in operating assets and liabilities:
Other receivable	(100,000)	—	—
Prepaid expenses and other current assets	(16,413)	(1,408)	(4,037)
Other non-current assets	4,389	(5,061)	15
Accounts payable	4,765	3,307	(860)
Accrued expenses and other current liabilities	21,514	7,717	12,163
Operating lease liabilities	(2,296)	(1,591)	(315)
Net cash used in operating activities	(222,199)	(116,636)	(79,488)
Cash flows from investing activities
Purchases of short-term investments	(547,379)	(702,519)	(417,356)
Proceeds from maturities of short-term investments	630,540	344,900	151,181
Purchases of property and equipment	(3,614)	(1,290)	(2,167)
Proceeds from sale of non-financial asset	10,249	—	—
Net cash provided by (used in) investing activities	89,796	(358,909)	(268,342)
Cash flows from financing activities
Proceeds from ATM Offering, net of sales commission	57,058	—	—
Proceeds from issuance of ordinary shares in 2025 Follow-On Offering, net of underwriting discounts and commissions	608,650	—	—
Proceeds from issuance of pre-funded warrants in 2025 Follow-On Offering, net of underwriting discounts and commissions	94,000	—	—
Proceeds from issuance of ordinary shares in 2024 Follow-On Offering, net of underwriting discounts and commissions	—	514,573	—
Proceeds from issuance of ordinary shares in initial public offering, net of underwriting discounts and commissions	—	—	172,296
Proceeds from private placement financing, gross	—	—	300,000
Payments of offering costs	(2,020)	(1,796)	(21,565)
Proceeds from issuance of ordinary shares under employee share purchase plan	921	632	—
Proceeds from exercise of share options	4,525	1,854	800
Payment of taxes on restricted share units withheld for taxes	(618)	—	—
Net cash provided by financing activities	762,516	515,263	451,531
Net change in cash and cash equivalents	630,113	39,718	103,701
Cash and cash equivalents
Beginning of the period	169,510	129,792	26,091
End of the period	$799,623	$169,510	$129,792
Supplemental disclosures of noncash investing and financing activities
Offering costs included in accounts payable and accrued expenses and other current liabilities	$442	$100	$53
Operating lease right-of-use assets obtained in exchange for new lease liabilities	$4,921	$—	$5,508
Depository issuance cost offset	$1,531	$—	$—
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	$894	$—	$48
Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering	$—	$—	$199,975
Recognition of asset retirement obligation	$—	$—	$277
Conversion of non-voting ordinary shares into ordinary shares	$—	$—	$1
Exchange of ordinary shares to non-voting ordinary shares	$—	$—	$1

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.